1. Scrip
  3. >>Alimentary/Metabolic

Takeda quiet on possible $2bn+ Actos settlement

 
• By Ian Haydock

Despite a report that it may be considering settling thousands of US lawsuits relating to its former blockbuster diabetes drug Actos, Takeda Pharmaceutical has so far given no indications it intends to do so.

Despite a report that it may be considering settling thousands of US lawsuits relating to its former blockbuster diabetes drug Actos, Takeda Pharmaceutical has so far given no indications it intends to do so.

While a media report earlier this month suggested that Takeda has already offered to pay a total of $2.2bn to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.